EMA: No biowaivers for NTIDs [Dissolution / BCS / IVIVC]

posted by Helmut Homepage – Vienna, Austria, 2020-07-15 19:08 (277 d 06:33 ago) – Posting: # 21704
Views: 1,194

Hi dshah,

» We are working on a NTI drug with high variability for which different dissolution media is recommended by USFDA.
» For BE study as per USFDA- a fasting and fed study for highest strength is recommended.

Why don’t you simply tell us that the drug is rivaroxaban? :-D

» For EMA- A fed study on highest strength and a fasting study on another mid strength is concluded based on guideline.

Fine. Though there is no product-specific guidance for rivaroxaban publishd by the EMA, most people would consider it an NTID indeed. Following the logic of other NTID-guidances that would mean acceptance limits of 80.00–125.00% for Cmax and 90.00–111.11% for AUC. In rare cases the limits of Cmax have to narrowed as well. Up to you to provide a justification.

» For waiver request for other strength we need acceptable in vitro dissolution testing of all strengths.

Biowaivers for NTIDs are not acceptable. BE-Guideline APPENDIX III:

Applying for a BCS-based biowaiver is restricted to highly soluble drug substances with known human absorption and considered not to have a narrow therapeutic index.


Dif-tor heh smusma 🖖
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

Activity
 Admin contact
21,419 posts in 4,475 threads, 1,509 registered users;
online 9 (0 registered, 9 guests [including 4 identified bots]).
Forum time: Monday 01:41 CEST (Europe/Vienna)

There is one certainty in drug development
and statistics that one can depend on:
the data are always late.    Scott Patterson and Byron Jones

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5